Shares of MacroCure Ltd. (NASDAQ:MCUR) have received a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.

Brokers have set a 12-month consensus price target of $1.50 for the company, according to Zacks. Zacks has also assigned MacroCure an industry rank of 109 out of 265 based on the ratings given to its competitors.

Separately, Credit Suisse Group AG cut shares of MacroCure from a “neutral” rating to an “underperform” rating and set a $1.00 target price on the stock. in a report on Monday, July 18th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

An institutional investor recently raised its position in MacroCure stock. Renaissance Technologies LLC raised its position in MacroCure Ltd. (NASDAQ:MCUR) by 25.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 186,500 shares of the company’s stock after buying an additional 37,700 shares during the period. Renaissance Technologies LLC owned 1.12% of MacroCure worth $166,000 at the end of the most recent reporting period. 2.76% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MacroCure (NASDAQ:MCUR) traded down 6.84% during trading on Wednesday, reaching $1.77. 276,077 shares of the company traded hands. The company has a 50 day moving average price of $1.53 and a 200 day moving average price of $1.32. The firm’s market capitalization is $31.34 million. MacroCure has a 12-month low of $0.75 and a 12-month high of $4.26.

MacroCure Company Profile

MacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.

5 Day Chart for NASDAQ:MCUR

Get a free copy of the Zacks research report on MacroCure (MCUR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for MacroCure Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroCure Ltd. and related companies with's FREE daily email newsletter.